Bioniche Achieves Two Additional Milestones Under Licensing Agreement; Endo Takes up Global Rights

BELLEVILLE, ON, Feb. 12 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. (TSX: BNC), a research-based, technology driven Canadian biopharmaceutical company, today announced that it has met the obligations associated with two milestones under its licensing agreement with Endo Pharmaceuticals ( ENDP) for exclusive rights to develop and market Bioniche's proprietary product for non-muscle-invasive bladder cancer in North America. The achievement of these milestones triggers a total payment of...